ODI Pharma AB Profit Margin

The latest profit margin for ODI.ST is 4.7% as of June 2026. That compares with -195.7% in the prior-year period — up 102.4% year over year. That is below the sector sector average of 13.4%. Investors often review this figure alongside ODI Pharma AB's historical trend and sector peers before judging valuation or financial health.

Over the past year, ODI.ST's profit margin moved from -195.7% to 4.7% — a 102.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ODI Pharma AB's valuation or profitability profile.

Against its sector companies, ODI.ST currently prints 4.7% for profit margin, while the sector average sits near 13.4%. That is roughly 65.0% below the sector mean. Large gaps often invite a closer look at ODI Pharma AB's growth, margins, and balance sheet.

Profit Margin shows how effectively ODI Pharma AB converts resources into returns. At 4.7%, ODI.ST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -195.7% in the prior-year period — up 102.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ODI.ST's profit margin (4.7%), review year-over-year change from -195.7%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.